Valuation: Valneva SE

Market Cap 495M 557M 463M 422M 794M 53.68B 805M 5.6B 2.17B 27.34B 2.09B 2.05B 87.8B P/E 2026 *
-5.99x
P/E 2027 * 9.45x
Enterprise Value 629M 708M 588M 536M 1.01B 68.17B 1.02B 7.11B 2.75B 34.72B 2.66B 2.6B 112B EV / Sales 2026 *
4.16x
EV / Sales 2027 * 1.97x
Free-Float
89.26%
Yield 2026 *
-
Yield 2027 * -
1 day-5.34%
1 week+1.65%
Current month-0.07%
1 month-3.83%
3 months+20.47%
6 months-3.79%
Current year-27.58%
1 week 2.62
Extreme 2.624
2.77
1 month 2.62
Extreme 2.624
3.02
Current year 2.11
Extreme 2.109
5.05
1 year 2.11
Extreme 2.109
5.05
3 years 1.77
Extreme 1.768
6.37
5 years 1.77
Extreme 1.768
28.02
10 years 1.77
Extreme 1.768
28.02
Manager TitleAgeSince
Chief Executive Officer 62 -
Director of Finance/CFO 56 2021-07-28
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Director/Board Member 62 2023-12-19
Director/Board Member 75 2013-03-06
Chairman 65 2023-12-19
Change 5-day change 1-year change 3-year change Capi.($)
-5.31%+1.65% - - 557M
+4.16%+3.04%+49.37%+94.17% 74.41B
-0.78%-1.21%+24.85%+78.80% 59.26B
-0.61%-1.65%+4.86%+31.72% 47.14B
-3.02%-5.20%+27.94%+32.51% 42.91B
+0.31%+3.02%+348.95%+643.82% 44.13B
-1.96%-0.33%+7.04%+99.46% 40.79B
+3.32%+3.49%+10.10%+51.23% 30.77B
-3.03%+2.55%+29.16%+22.27% 29.31B
-4.86%-10.66%-26.27%+330.06% 23.71B
Average -1.18%-0.52%+52.89%+153.78% 43.6B
Weighted average by Cap. -0.17%-0.32%+58.11%+145.48%

Financials

2026 *2027 *
Net sales 151M 170M 141M 129M 242M 16.37B 246M 1.71B 661M 8.34B 638M 624M 26.78B 283M 319M 265M 241M 455M 30.72B 461M 3.21B 1.24B 15.64B 1.2B 1.17B 50.25B
Net income -81.11M -91.32M -75.86M -69.13M -130M -8.79B -132M -918M -355M -4.48B -343M -335M -14.38B 53.07M 59.75M 49.63M 45.23M 85.15M 5.75B 86.32M 600M 232M 2.93B 224M 219M 9.41B
Net Debt 134M 151M 125M 114M 215M 14.49B 217M 1.51B 586M 7.38B 565M 553M 23.71B 62.48M 70.34M 58.43M 53.24M 100M 6.77B 102M 707M 274M 3.45B 264M 258M 11.08B
Logo Valneva SE
Valneva is a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. Valneva takes a highly specialized and targeted approach, applying its deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions. Valneva has a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently markets three proprietary travel vaccines. Revenues from its growing commercial business help fuel the continued advancement of its vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against other global public health threats.
Employees
620
Date Price Change
26-09-28 €2.713 -2.20%
26-10-01 €2.624 -3.35%
26-09-30 €2.715 +0.07%
26-09-29 €2.713 -2.20%
26-09-28 €2.774 +4.68%
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.611EUR
Average target price
6.193EUR
Spread / Average Target
+137.18%

Quarterly revenue - Rate of surprise